In this moment, we're building the steam engine for this new natural resource—data. We must ensure that we build it not only ...

If there’s a situation where you and your friend need to collaborate on diagrams in a project simultaneously, what would you do? Naturally, team up and work with him but what if they reside in two ...

SHEBOYGAN – Sheboygan’s Uptown Social has surpassed 2,000 members since opening its doors in November 2022, marking a major milestone for the city’s hub for active seniors. The center, at 1817 N.

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced ...

– Milestone Payment Triggered by Initiation of Additional Preclinical Studies for REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia – NEW HAVEN, Conn.--(BUSINESS ...

Pull requests help you collaborate on code with other people. As pull requests are created, they’ll appear here in a searchable and filterable list. To get started, you should create a pull request.

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...

NEW HAVEN, Conn. - Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company currently trading near $0.34 per share, has agreed to sell its interest in REV102, a preclinical ENPP1 ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn., July 08, 2025--(BUSINESS ...

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...